A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection

Clinical Infectious Diseases

Volumn 62, Issue 5, 2016, Pages 545-551

  Dunne, Michael W ^a   Puttagunta, Sailaja ^a   Giordano, Philip ^b   Krievins, Dainis ^c   Zelasky, Michael ^a   Baldassarre, James ^d  

^a Iterum Therapeutics US Ltd   (United States)

^b ORLANDO HEALTH   (United States)

^c PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clinical trial; Dalbavancin; Efficacy; Methicillin resistant Staphylococcus aureus; Skin infection

Indexed keywords

DALBAVANCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ABNORMAL LABORATORY RESULT; ABSCESS; ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; CELLULITIS; CONTROLLED STUDY; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HEADACHE; HEPATITIS C; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SURGICAL INFECTION; TREATMENT RESPONSE; VOMITING; ACUTE DISEASE; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN;

EID: 84960145339     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ982     Document Type: Article

References (16)

1. Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008; 51:292-8.
2. David MZ, Medvedev S, Hohmann SF, Ewigman B, Daum RS. Increasing burden of methicillin-resistant Staphylococcus aureus hospitalizations at US academic medical centers, 2003-2008. Infect Control Hosp Epidemiol 2012; 33:782-9.
3. David MZ, Daum RS, Bayer AS, et al. Staphylococcus aureus bacteremia at five U.S. academic medical centers, 2008-2011: significant geographic variation in community-onset infections. Clin Infect Dis 2014; 15:798-807.
4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
5. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillinresistant Staphylococcus aureus. N Engl J Med 2007; 357:380-90.
6. Andes D, CraigWA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007; 51:1633-42.
7. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005; 55(suppl 2):ii25-30.
8. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2012; 56:2795-805.
9. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis or non-zero risk difference or non-unity relative risk. Stat Med 1990; 9:1447-54.
10. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26.
11. Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:2169-78.
12. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407-15.
13. Dunne MW, Zhou M, Borje Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skinstructure infections. Int J Antimicrob Agents 2015; 45:393-8.
14. Tice AD, Rehm SJ, Dalvasio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 2004; 38:1651-72.
15. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010; 51:895-903.
16. Jenkins TC, Knepper BC, Sabel AL, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med 2011; 171:1072-9.